Evidence map›Paper›PMID 25633184›Full record

ArticleBMC cancer2015

Caveolin-1 accumulation in the tongue cancer tumor microenvironment is significantly associated with poor prognosis: an in-vivo and in-vitro study.

Marilena Vered, Meri Lehtonen, Lari Hotakainen, Emma Pirilä, Susanna Teppo, Pia Nyberg, Raija Sormunen, Ayelet Zlotogorski-Hurvitz, Tuula Salo, Dan Dayan

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Placental-Cadherin, a biomarker for local immune status and poor prognosis among patients with tongue squamous cell carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. The Microenvironment of Tongue Cancer.Advances in experimental medicine and biology · 2020
    Review
  13. Article
  14. Exosomes in head and neck cancer. Updating and revisiting.Journal of enzyme inhibition and medicinal chemistry · 2019
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Organotypic three-dimensional assays based on human leiomyoma-derived matrices.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Marilena VeredDepartment of Oral Pathology and Oral Medicine, School of Dental Medicine, Tel Aviv University, Tel Aviv, 69978, Israel. mvered@post.tau.ac.il.
Meri LehtonenDepartment of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu, Oulu, Finland. meri.lehtonen@hotmail.fi.
Lari HotakainenDepartment of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu, Oulu, Finland. Lari.Hotakainen@student.oulu.fi.
Emma PiriläDepartment of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu, Oulu, Finland. emma.pirila@oulu.fi.
Susanna TeppoDepartment of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu, Oulu, Finland. susanna.teppo@gmail.com.
Pia NybergDepartment of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu, Oulu, Finland. pia.nyberg@oulu.fi.
Raija SormunenBiocenter Oulu, University of Oulu, Oulu, Finland. raija.sormunen@oulu.fi.
Ayelet Zlotogorski-HurvitzDepartment of Oral Pathology and Oral Medicine, School of Dental Medicine, Tel Aviv University, Tel Aviv, 69978, Israel. ayelet.zlotogorski@gmail.com.
Tuula SaloDepartment of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu, Oulu, Finland. tuula.salo@oulu.fi.
Dan DayanDepartment of Oral Pathology and Oral Medicine, School of Dental Medicine, Tel Aviv University, Tel Aviv, 69978, Israel. ddayan@post.tau.ac.il.
University of Oulu · FITel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCaveolin-1 (CAV1) may be upregulated by hypoxia and acts in a tumor-dependent manner. We investigated CAV1 in tongue squamous cell carcinoma (TSCC) and its association with clinical outcomes, and studied in vitro possible ways for CAV1 accumulation in the tumor microenvironment (TME).

methodsTSCC cases (N = 64) were immunohistochemically stained for CAV1. Scores were separately assessed in the tumor and TME and plotted for association with recurrence and survival (univariate analysis with log-rank test). In vitro studies were performed on a 3D myoma organotypic model, a mimicker of TME. Prior to monoculturing HSC-3 tongue cancer cells, the model underwent modifications in oxygenation level (1%O2 hypoxia to upregulate CAV1) and/or in the amount of natural soluble factors [deleted by 14-day rinsing (rinsed myoma, RM), to allow only HSC-3-derived factors to act]. Controls included normoxia (21%O2) and naturally occurring soluble factors (intact myoma, IM). HSC-3 cells were also co-cultured with CaDEC12 cells (fibroblasts exposed to human tongue cancer). CAV1 expression and cellular distribution were examined in different cellular components in hypoxic and rinsed myoma assays. Twist served as a marker for the process of epithelial-mesenchymal transition (EMT). Exosomes isolated from HSC-3 media were investigated for containing CAV1.

resultsExpression of CAV1 in TSCC had a higher score in TME than in the tumor cells and a negative impact on recurrence (p = 0.01) and survival (p = 0.003). Monocultures of HSC-3 revealed expression of CAV1 mainly in the TME-like myoma assay, similar to TSCC. CAV1+, alpha-smooth muscle actin (αSMA) + and Twist + CAF-like cells were observed surrounding the invading HSC-3, possibly reflecting EMT. RM findings were similar to IM, inferring action of HSC-3 derived factors, and no differences were seen when hypoxia was induced. HSC-3-CaDEC12 co-cultures revealed CAV1+, αSMA+ and cytokeratin-negative CAF-like cells, raising the possibility of CaDEC12 cells gaining a CAF phenotype. HSC-3-derived exosomes were loaded with CAV1.

conclusionsAccumulation of CAV1-TME in TSCC had a negative prognostic value. In vitro studies showed the presence of CAV1 in cancer cells undergoing EMT and in fibroblasts undergoing trans-differentiation to CAFs. CAV1 delivery to the TME involved cancer cell-derived exosomes.

Indexed as

Tumor MicroenvironmentAdultAgedCarcinoma, Squamous CellCaveolin 1Cell Culture TechniquesCoculture TechniquesFemaleFollow-Up StudiesGene ExpressionHumansImmunohistochemistryMaleMiddle AgedNeoplasm StagingPrognosisCaveolin 1

Identifiers

PMID25633184
PMCPMC4318139
OpenAlexW2045313648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.